CytomX Therapeutics Inc. (United States) is listed on the Nasdaq and has a market capitalization of $454.65 million, with shareholders equity totaling $284.89 million.
The company employs approximately 160 people and operates in the Health Care sector, within the Biotechnology industry.
Over the past 12 months, CytomX Therapeutics Inc. reported $14.03 million in revenue, generating net income of $-85.42 million.
Key financial metrics include a P/E ratio of -5.32, a price-to-book (P/B) ratio of 1.60, and a trailing twelve-month dividend yield of 0.00%.
The company trades under the ticker CTMX.